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ABSTRACT
The free â-subunit of human chorionic gonado-
trophin (hCGâ) is well recognised as a product of
many epithelial tumours. Recently, it has been
shown that this ectopic production may have a
functional relationship to tumour growth. The
growth-promoting activity of hCGâ may be
explained by its structural similarity to a family of
growth factors which all contain the same distinct
topological fold known as the cystine-knot motif.
Since the other members of this family all exhibit
their activities as homo- and heterodimers, it is
possible that the same may be true for hCGâ.
Using size-exclusion chromatography, low strin-
gency SDS-PAGE and matrix assisted laser
desorption/ionisation (MALDI) time-of-flight (TOF)
mass spectrometry (MS) we have shown that pure
preparations of hCGâ contain hCGââ homodimers.
Size-exclusion chromatography revealed asymmetric
elution profiles with a forward peak corresponding to
the size-exclusion characteristic of a globular protein
with an approximate mass of 44–54 kDa and a late
shoulder centered around an elution position expected
for a globular protein of approximately 29 kDa. Two
immunoreactive hCGâ species, of approximately 32
and 64 kDa, were clearly resolved by SDS-PAGE and
Western blotting. When analysed by MALDI-TOF
MS a 223 kDa monomer and a 246 kDa dimer were
identified.
Formation of hCGââ homodimers is consistent
with the behaviour of other cystine-knot growth
factors and strengthens the inclusion of the glyco-
protein hormones within this superfamily. It has yet
to be determined whether it is this dimeric molecular
species that is responsible for growth-promoting
activity of hCGâ preparations in tumours.
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INTRODUCTION
Human chorionic gonadotrophin (hCG) is a
member of the glycoprotein hormone family, which
also includes luteinising hormone (LH), follicle-
stimulating hormone and thyroid-stimulating
hormone, all existing as Æâ heterodimers. The Æ-
subunit is common to all members of the group and
it is the â-subunits which confer the structural and
functional identity of the heterodimer. Further-
more, only the intact heterodimer is functional; the
free subunits do not exhibit gonadotrophic or
thyrotrophic activity. Therefore, any growth factor
activity exhibited by the free â-subunit is generally
regarded not to occur through the LH/hCG
receptor, but via a novel pathway.
The free â-subunit of hCG (hCGâ) is widely
used as a marker of Down’s syndrome (Spencer
et al. 1992, Cuckle et al. 1994) and has been
proposed as a prognostic marker for many epithelial
tumours (Iles et al. 1996). In both situations the
expression of hCGâ was regarded as having no
biological significance. However, it has now been
shown that the â-subunit may have its own unique
functions. Lunardi-Iskandar et al. (1995) and
Gillott et al. (1996) have shown growth inhibitory
and growth stimulatory eVects respectively of free
hCGâ. Recently, elucidation of the crystal structure
of hCG revealed a similar topology between hCGâ
and transforming growth factor â (TGFâ), platelet
derived growth factor â (PDGFâ) and nerve cell
growth factor (NGF) (Lapthorn et al. 1994, Wu
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et al. 1994). The feature common to all four
molecules is a unique group of three disulphide
bridges in the centre of the molecule, the so called
‘cystine-knot motif’. It is interesting to note that the
cystine-knot growth factors mediate their biological
activity through the formation of homo- and/or
heterodimers. In view of the recently reported
biological activity of hCGâ (Gillott et al. 1996) and
the structural similarities within this group of
proteins, we have investigated the possible existence
of an hCGââ homodimer using size-exclusion
chromatography, SDS-PAGE and matrix-assisted
laser desorption/ionisation (MALDI) time-of-flight
(TOF) mass spectrometry (MS).
MATERIALS AND METHODS
Recombinant hCGâ subunit, which is expressed in
a mammalian cell line, containing N- and O-linked
carbohydrate moieties similar to those in authentic
hCGâ, was purchased from Sigma Chemical Co.
(Poole, Dorset, UK). The international reference
preparation of free hCGâ, CR123, which is derived
from splitting intact heterodimeric hCG isolated
from pregnancy urine, was a kind gift from Dr
Steven Birken (Columbia University, New York,
USA) (Storring et al. 1980). MALDI matrices
Æ-cyano-4-hydroxycinnamic acid (CHCA), 2,5-
dihydroxybenzoic acid (DHB), 3,5-dimethoxy-4-
hydroxybenzoic acid (sinapinic acid (SA)) and
5-methoxysalicylic acid (MSA) were purchased
from Aldrich Chemical Co. (Gillingham, Dorset,
UK) and used without further purification.
Size-exclusion gel chromatography
Recombinant hCGâ and CR123 preparation hCGâ
(100 µl at 50 µg/ml in 1% w/v BSA–PBS) were
loaded onto a column (630 mm#10 mm internal
diameter) of Sephacryl S200HR via a Rheodyne
(Berkeley, CA, USA) injection loop. The samples
were then eluted with 0·1 M ammonium bicar-
bonate buVer (pH 7·4) by ascending flow at a rate
of 0·3 ml/min using a Shimadzu (Kyoto, Japan)
LC-6A HPLC pump. Eluted fractions (0·9 ml) were
collected into polystyrene tubes containing 100 µl
10% w/v BSA–PBS. BuVer containing BSA was
added to the collection tubes and at injection, in
order to reduce the non-specific absorption of the
proteins of interest to the column components and
fraction vessels.
The column was calibrated using gel-exclusion
chromatography globular protein markers (Sigma):
Blue dextran (700 kDa – void volume), alcohol
dehydrogenase (150 kDa), BSA (66 kDa) and
carbonic anhydrase (29 kDa).
Assay for hCGâ
Fractions eluting from the size-exclusion column
were assayed for total hCGâ using an in-house
polyclonal RIA. This assay has been described by
Iles (1991) and uses a polyclonal antiserum, S424,
raised against the â-subunit of hCG, as binder and
125I-labelled CR123 free hCGâ as tracer. This assay
recognises the â-subunit of hCG in the heterodimer
of intact hCG, as the free subunit and the hCGâ
degradation product â-core.
SDS PAGE and Western blotting
Electrophoresis was essentially carried out by the
method described by Laemmli (1970). Recombinant
hCGâ samples were separated on 10% acrylamide
gels under both reducing and low stringency
conditions using the Mighty Small II gel system
(Hoefer, Amersham Pharmacia Biotech, St Albans,
Herts, UK). Ten-microlitre samples of the recom-
binant hCGâ preparation (100 µg/ml) were com-
bined with an equivolume of either non-reducing
sample buVer (125 mM Tris–HCl, pH 6·8, 20%
glycerol, 4% SDS, 0·02% bromophenol blue) or
reducing sample buVer (containing 10% â-
mercaptoethanol) before separation. The reducing
sample was additionally heated for 3 min in a
boiling water bath to ensure complete reduction of
the thiol moieties; the low stringency sample was
not heated. In both cases 14C-labelled Rainbow
Molecular Mass Markers (Amersham Pharmacia
Biotech) were subjected to the same conditions as
the corresponding sample prior to separation. The
separated proteins were transferred to polyvinyl-
idene difluoride nylon membrane (Immobilon-P,
Millipore, Sigma) using the Biometra Fastblot
B32 semi-dry blotter (Anachem-Scotlab, Luton,
Beds, UK), blocked, then probed overnight with
monoclonal anti-hCGâ 1/07 (Quantum Biosystems
Ltd, Cambridge, Cambs, UK) labelled with 125I by
the chloramine-T method of Greenwood et al.
(1963). Following multiple washes with PBS 0·1%
Tween 20 (Sigma) the blot was exposed to Kodak
X-OMAT AR imaging film and developed using
the Kodak M35 X-OMAT processor (Kodak,
Hemel Hempstead, Herts, UK).
MALDI-TOF MS
The matrices selected for this work are used widely
in MALDI analysis, SA and a 9:1 (w/w) mixture of
DHB with MSA, referred to as super-DHB
s a butler and others · hCGââ homodimer186
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(sDHB), being particularly useful for the analysis of
glycoproteins (Kussmann et al. 1997). In addition,
CHCA was chosen because relative to SA or sDHB
it has a lower proton aYnity (Burton et al. 1997) and
is therefore more liable to favour dissociation of
non-covalent complexes. Matrix solutions were
prepared using HPLC grade acetonitrile (Fisher
Scientific UK Ltd, Loughborough, Leics, UK) and
purified water (Elgastat UHQ, High Wycombe,
Bucks, UK). Solutions of SA and CHCA were
prepared at 10 g/l in acetonitrile/water (70:30, v/v).
sDHB (a 9:1 (w/w) mixture of DHB with MSA)
(Karas et al. 1993), was prepared at a concentration
of 20 g/l in acetonitrile/water (30:70, v/v). Recom-
binant hCGâ and the international reference
preparation were prepared to concentrations of 0·8
and 0·4 mg/ml respectively in purified water.
Half-microlitre aliquots of hCGâ sample were
mixed on the MALDI sample support with 0·5-1 µl
matrix solution and allowed to air dry. Spectra were
then generated using a LASERMAT 2000 mass
spectrometer (Thermo Bioanalysis Ltd, Hemel
Hempstead, Herts, UK). Light from a pulsed
nitrogen laser (ºmax=337 nm) was used to desorb
ions from the samples and they were accelerated
down a 0·5 m drift tube and detected by a
micro-channel plate detector. The detector signal
was digitised at a sampling rate of 500 MHz and
transferred to a personal computer for data analysis.
Spectra were generated by summing 20–35 laser
shots and were calibrated externally using horse
heart cytochrome C (12 360 Da) (Sigma).
RESULTS
Size-exclusion chromatography
The chromatogram of recombinant hCGâ revealed
an asymmetric elution profile of immunoreactive
material consisting of a forward peak eluting at a
position corresponding to the Stokes’ radius of a
globular protein of approximately 44 kDa in mass
and a late shoulder approximating to a globular
protein of 29 kDa. CR123â eluted in a similar
manner with a forward peak of 244–54 kDa and a
late shoulder of 229 kDa (Fig. 1).
SDS PAGE and Western blotting
Under low stringency (non-reducing) conditions
two protein bands were separated by SDS-PAGE
and following Western blotting were identified
immunologically as hCGâ. The band with the
higher molecular mass (hCGâ dimer) was exactly
double (264 kDa) that of the lower band
corresponding to hCGâ monomer (232 kDa).
Under reducing conditions the same hCGâ prep-
aration gave rise to only one band corresponding to
hCGâ monomer (32 kDa) (Fig. 2).
MALDI-TOF MS
MALDI-TOF mass spectra of recombinant hCGâ
analysed in SA, sDHB and CHCA matrices are
shown in Figs 3, 4 and 5 respectively. All the
spectra were characterised by peaks corresponding
to the singly (m/z 223 kDa) and doubly (m/z
211·5 kDa) charged ions of hCGâ. Spectra gener-
ated in sDHB and SA also contain a peak at m/z
figure 1. Sephacryl S200HR size-exclusion
chromatography elution profiles of recombinant and
CR123 hCGâ preparations. Arrows mark the elution
maxima of gel-exclusion chromatography globular
protein markers: alcohol dehydrogenase (150 kDa), BSA
(66 kDa) and carbonic anhydrase (29 kDa). Void volume
(Vo) was determined as the elusion maxima for Blue
dextran (2700 kDa).
figure 2. Scanned autoradiograph showing a Western
blot of separated recombinant hCGâ under reducing
and low stringency conditions, probed with
125I-anti-hCGâ monoclonal antibody 1/07.
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246 kDa indicating the presence of a dimer of
hCGâ. This peak was absent from the spectra
acquired using CHCA as the matrix. The signal due
to the doubly charged monomer was considerably
more intense when CHCA was used as the matrix.
In addition, an ion corresponding to the trebly
charged hCGâ monomer was present in the CHCA
spectra. Peaks corresponding to the singly and
doubly charged ions of hCGâ were observed in the
spectrum of the international reference preparation
for hCGâ (CR123â) analysed in SA. The singly
charged ion of an hCGââ homodimer was also
present, albeit at low intensity (Fig. 6). The micro-
heterogeneous nature of hCGâ, due primarily
to variations in glycosylation, and in particular
sialic acid content, results in the broad peaks
characteristic of the generated spectra.
DISCUSSION
The ectopic production of free hCGâ is a
well-recognised phenomenon in many epithelial
tumours (Iles et al. 1990). Expression of hCGâ by
these cancers was originally thought to carry no
biological significance, but it is now apparent that
this event may significantly aVect tumour develop-
ment given the growth eVects described recently
(Gillott et al. 1996). Similarly hCGâ has also been
shown to induce regression in the AIDS-related
tumour Kaposi’s sarcoma (Lunardi-Iskandar et al.
1995) and several studies on both in vitro and in vivo
models report similar findings (Harris 1995, Gill
et al. 1996). However, opinions diVer as to the
figure 3. MALDI-TOF mass spectrum of
recombinant hCGâ (0·4 mg/ml) 0·5 µl with 0·5 µl SA
10 g/l in acetonitrile/water (70:30), showing peaks
corresponding to monomeric doubly charged hCGâ
(â2+), monomeric hCGâ (â+) and dimeric hCGâ (ââ+)
at approximately 11·5, 23 and 46 kDa respectively.
figure 4. MALDI-TOF mass spectrum of
recombinant hCGâ (0·8 mg/ml) 0·5 µl with 1 µl sDHB
20 g/l in acetonitrile/water (30:70), showing peaks
corresponding to monomeric doubly charged hCGâ
(â2+), monomeric hCGâ (â+) and dimeric hCGâ (ââ+)
at approximately 11·5, 23 and 46 kDa respectively.
figure 5. MALDI-TOF mass spectrum of
recombinant hCGâ (0·8 mg/ml) 0·5 µl with 0·5 µl CHCA
10 g/l in acetonitrile/water (70:30), showing peaks
corresponding to monomeric trebly charged hCGâ
(â3+), monomeric doubly charged hCGâ (â2+), and
monomeric hCGâ (â+) at approximately 7·7, 11·5 and
23 kDa respectively.
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identity of the actual functional component(s) in the
preparations used in these studies; intact hCG
(Harris 1995), hCGâ (Lunardi-Iskander et al.
1995), â-core (Kachra et al. 1997), the carboxy-
terminal peptide of hCGâ (Albini et al. 1997) and
an hCG associated factor, HAF (Lunardi-Iskandar
et al. 1998), which may be a ribonuclease inhibitor
(GriYths et al. 1997), have all been proposed as the
active molecule.
The individual Æ- and â-subunits of hCG share a
distinctive topological folding pattern, known as the
cystine-knot motif, with the growth factors TGFâ,
NGF and PDGFâ (Murray-Rust et al. 1993, Sun &
Davies 1995). Although all these growth factors
bind to quite diVerent receptor families, biological
activity is achieved only through the formation of
either hetero- and/or homodimers. TGFâ signalling
in particular requires a ââ homodimer and PDGFâ
forms ââ homodimers which initiate second
messenger phosphorylation; PDGFâÆ heterodimers
and PDGFÆÆ homodimers are also known to
initiate and control kinase activity (Heath 1993).
The TGF and PDGF ââ homodimers are bound
together ‘top to tail’ to yield the structure required
for receptor binding and activation. This subunit
association is very similar to that seen within the
hCG heterodimer, in which the carboxy-terminal
sequence of the â-subunit wraps around the
Æ-subunit in a ‘seatbelt’ arrangement (Lapthorn
et al. 1994). These structural similarities, together
with the recently described growth-promoting
activity of hCGâ (Gillott et al. 1996), suggest that
the action may be brought about by an hCGââ
homodimer. It is notable that homodimers of the
Æ- and â-subunits of bovine LH have also been
reported (Peng et al. 1997).
Furthermore it has been indicated that in high
concentrations, â-core, a breakdown product of
hCG and hCGâ, can also form homodimers (Iles
1991). In view of the very similar folding patterns of
hCGâ and these growth factors, a possible
candidate to mediate the growth factor activities of
hCGâ is a putative hCGââ homodimer. Since free
hCGâ is unable to activate the LH/hCG receptor
and stimulate secondary messengers, the reported
growth factor activities are assumed to proceed via
novel, and as yet unidentified, pathways.
Our data support the existence of hCGââ
homodimers in preparations of hCGâ which have
previously been shown to exhibit growth factor
activities. Intact hCG and free hCGâ have always
been found to behave unusually on size-exclusion
chromatography, eluting close to the void volume
and at the expected position of human serum
albumin (270 kDa) on Sephadex G-100 size-
exclusion columns (Bell et al. 1969, Canfield et al.
1971). This phenomenon is due to the extensive
glycosylation of hCG and hCGâ, which aVords
them Stokes’ radii equivalent to globular molecules
of over twice their mass (Butt et al. 1994). In this
study we used Sephacryl 200HR size-exclusion
matrix, which should resolve molecules with a
Stokes’ radius of approximately 70 kDa in the
middle of its chromatographic range (Kardana et al.
1991). As can be seen from Fig. 1 the major peak of
hCGâ eluted at 244–55 kDa but a significant late
shoulder eluted at 229 kDa. SDS-PAGE was more
definitive with two species being resolved at 232
and 264 kDa respectively. With SDS-PAGE these
species were only seen together when separated
under low stringency conditions in which the
sample was only exposed to SDS, non-reducing
conditions and not boiled. Heating alone is
suYcient to disrupt the Æâ heterodimer of intact
hCG releasing free subunits (Gau et al. 1984,
Sancken & Bahner 1995) despite the seatbelt on the
â-subunit holding the Æ-subunit in tight association.
When stringent conditions of a disulphide reducing
agent (â-mercaptoethanol), SDS and heating were
employed only the 232 kDa (monomeric) species
could be seen (Fig. 2). The diVerences in
assignment of molecular mass of the species
between size-exclusion chromatography and SDS-
PAGE can be ascribed to the imprecision of these
techniques, which can only approximate molecular
masses.
figure 6. MALDI-TOF mass spectrum of CR123â
(0·4 mg/ml) 0·5 µl with 0·5 µl SA (acetonitrile/water),
showing peaks corresponding to monomeric doubly
charged hCGâ (â2+), monomeric hCGâ (â+) and
dimeric hCGâ (ââ+) at approximately 11·5, 23 and
46 kDa respectively.
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To optimise matrix-assisted ionisation in
MALDI, the sample is generally mixed with
a roughly equivalent volume of matrix, usually a
cinnamic or benzoic acid derivative, dissolved in
a mixture of acetonitrile and water/0·1% trifluoro-
acetic acid; the acidic nature of these conditions
is generally considered to be suYcient to disrupt
quaternary structures in most circumstances
(Hillenkamp et al. 1991, Cohen et al. 1997).
Nevertheless, in an earlier study we were able to
demonstrate the quaternary structure of the intact
hCG heterodimer by MALDI-TOF using an SA
matrix (Laidler et al. 1995) and in this current
investigation we have observed a mass ion akin to
that expected of the ââ homodimer in SA and
sDHB matrices. Of course, such mass spectral data
alone are not unequivocal in showing the presence
of the ââ homodimer because proteins may form
dimers during ionisation. For that reason, we chose
also to analyse the preparations of hCGâ using
CHCA, which is a more acidic matrix than SA or
sDHB. As the subunits of hCG may be separated
under very acidic conditions (Morbeck et al. 1994),
it is reasonable to expect the same to be the case for
a ââ homodimer. Recent work relating to the proton
aYnities of commonly used MALDI matrices
demonstrated that CHCA has a lower proton
aYnity (183&2 kcal/mol), and is therefore a
stronger acid, than either DHB or SA (both
204&4 kcal/mol) (Burton et al. 1997). On that
basis, the peak ascribed to the ââ homodimer, which
was observed in the sDHB and SA matrices, would
be expected to be attenuated when the CHCA
matrix was employed, unless the peak was an
artefact due to the ionisation process. Using the
CHCA matrix, the peak was so attenuated as for it
to be impossible to locate the homodimer. Hence,
the contrast in results by MALDI, using diVerent
matrices, also supports the presence of the ââ
homodimer.
An important factor that influences the stability
of the quaternary structure in the heterodimer, and
by implication the ââ homodimer, is the large
contact surface area between the two interacting
subunits; a surface area of approximately 4000 Ar is
buried by subunit binding (Lapthorn et al. 1994,
Wu et al. 1994). The amount of contact surface area
of the heterodimer is in contrast to the area of
600–900 Ar (Novotny et al. 1983, Amit et al. 1986) of
an antibody–antigen complex which is completely
dissociated by MALDI sample preparation (Nelson
et al. 1995).
The quaternary structure of a ââ homodimer
could be similar in nature to that of the hCGÆâ
heterodimer. The individual subunits are aligned
within the heterodimer in a ‘head to tail’ manner
and are stabilised by a structure, nicknamed
the seatbelt, formed when residues 90–110 of the
â-subunit wrap around the Æ-subunit before the
formation of a last disulphide bond between
residues 26 and 110 of the â-subunit. While
formation of the cystine residue 26–110 prior to
subunit contact would appear to hinder extra-
cellular subunit association (Huth et al. 1993), the
seatbelt also presents a barrier to heterodimer
dissociation; hCG exists in the circulation at
concentrations of 10"9 to 10"11 M despite an
equilibrium constant for subunit interaction of
approximately 10"6 M (Strickland & Puett 1982,
Ryan et al. 1988). One may expect a mature
ââ homodimer to be more stable than the hCGÆâ
heterodimer since its dissociation into hCGâ
monomers could require two seatbelt-like struc-
tures to be reduced rather than one. Should this
be the case, it is likely that an hCGââ species
intermediate between the monomer and a fully
stable hCGââ homodimer, containing only one
seatbelt, also exists. We would expect such an
intermediate species to exhibit a stability similar to
that of the hCGÆâ heterodimer.
Since biological activities, not mediated through
the LH/hCG receptor, have been described for both
the Æ- and â-subunits it is reasonable to suggest that
a novel molecular structure may be involved (Blithe
et al. 1991, Blithe 1994, Lunardi-Iskandar et al.
1995, Gillott et al. 1996). The experimental data
presented here suggest that a ââ homodimer is a
possible mediator of the previously reported growth
factor activities. The formation of such dimeric
molecular species may arise from post-translational
events such as glycosylation, which have, in the
Æ-subunit, been shown to prevent Æâ heterodimer
formation (Blithe et al. 1991). Similar modifications
in glycosylation of hCGâ may favour the formation
of the ââ homodimer rather than the Æâ hetero-
dimer. It is not yet known if homodimers form
in vivo, but the concentrations analysed here may
be comparable with local tissue concentrations. It
would, therefore, be feasible to suggest that a
proportion of ectopically produced free hCGâ may
exist as a homodimer.
It has not yet been determined whether the ââ
homodimer described here is responsible for the
growth-promoting activities of hCGâ. However,
the demonstration of an hCGââ homodimer makes
it less likely that the responses seen are due to
an interaction with the LH/hCG receptor and
reinforce the view that a novel receptor may be
involved. In addition, the predisposition of proteins
containing the cystine-knot motif to form homo-
dimers suggests that hCGâ may possibly form
heterodimers with other growth factor subunits,
s a butler and others · hCGââ homodimer190
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thereby creating unique molecules with multi-
functional roles.
In conclusion, the results from this investigation
support the presence of an hCGââ homodimer.
This unique species may be responsible for the
novel biological activities recently attributed to the
free â-subunit, and could play a key role in tumour
growth regulation and metastatic control.
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